Last edition
News about "Immunology Drug Development"
Johnson & Johnson Secures FDA Approval for Icotyde, First Oral IL-23 Inhibitor for Psoriasis
FDA approves Johnson & Johnson’s Icotyde, a first-in-class oral IL-23 receptor antagonist, offering a once-daily treatment option for moderate-to-severe plaque psoriasis in adults and adolescents.
Immunology Drug Development | 20/03/2026 | By News Bureau | 233
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members